mProX™ Human MSLN Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Mesothelin (MSLN) has been identified as a potential therapeutic target due to its unique characteristics. It is not expressed on vital organs, is differentially expressed on certain cancer types with poor prognosis, and is accessible to targeted therapies. However, the precise function and biological role of MSLN in cancer are not fully understood. The existing literature suggests that MSLN's function and prognostic significance may vary depending on the type of tumor. Researchers have developed strategies to enhance the function of MSLN-targeted T cells by incorporating chimeric switch receptors (CSRs) that co-opt the immunosuppressive PD-1/PD-L1 axis and deliver a costimulatory signal. These engineered T cells have shown improved effector function and resistance to exhaustion. Additionally, a novel human antibody VH domain targeting MSLN has been isolated and characterized, demonstrating high affinity and specificity. This antibody has the potential to be used as an antibody-drug conjugate for MSLN-expressing cancers. Further research is needed to fully understand the function and therapeutic implications of MSLN in cancer treatment.